Discovery of antibodies against challenging membrane protein targets using microencapsulation-assisted rare clone selection

Antibody-based medicines are playing an ever increasing role in the arsenal of treatments of many diseases, from cancer to obesity to Alzheimer’s. Cell surface proteins, called membrane receptors, are considered key therapeutic targets in many of these pathologies, yet targeting them with antibodies has proven to be a challenge. Amgen British Columbia is dedicated to the development of antibody therapies and is conducting pioneering research in this field. Current project is focused on the development of approaches that would enable efficient discovery of antibodies that can act upon complex membrane receptors and treat associated diseases. The approach, if successful, will be applicable to many targets that have so far evaded treatment.

Faculty Supervisor:

Paul Li;Robert Holt;Corey Nislow;Fumio Takei;Karen Cheung

Student:

Partner:

Amgen British Columbia

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Simon Fraser University; The University of British Columbia

Program: